RUBICON

Rubicon Research Share Price

 

Stock touched all time high

 

Invest in Rubicon Research with 3.38X leverage

Invest with MTF

Performance

  • Low
  • ₹758
  • High
  • ₹822
  • 52 Week Low
  • ₹571
  • 52 Week High
  • ₹822
  • Open Price₹779
  • Previous Close₹774
  • Volume975,676
  • 50 DMA₹667.73
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month + 19.47%
  • Over 3 Month + 21.08%
  • Over 6 Month + 62.93%
  • Over 1 Year + 62.93%

Smart Investing Starts Here Start SIP with Rubicon Research for Steady Growth!

Invest Now

Rubicon Research Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 13,019
  • P/B Ratio
  • 20.1
  • Average True Range
  • 28.95
  • EPS
  • 12.52
  • Dividend Yield
  • 0
  • MACD Signal
  • 6.79
  • RSI
  • 75.53
  • MFI
  • 82.16

Rubicon Research Financials

Rubicon Research Technicals

EMA & SMA

Current Price
₹790.20
+ 16.25 (2.1%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 11
  • 20 Day
  • ₹685.13
  • 50 Day
  • ₹667.73
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

763.78 Pivot Speed
  • R3 859.77
  • R2 824.38
  • R1 799.17
  • S1 738.57
  • S2 703.18
  • S3 677.97

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Rubicon Research develops, manufactures, and markets branded specialty and generic prescription drugs across the U.S. and other regulated markets. With two U.S. FDA-approved plants in Maharashtra and R&D centers in India and Canada, it offers diverse oral, nasal, and ophthalmic formulations.

Rubicon Research Ltd has an operating revenue of Rs. 2,313.88 Cr. on a trailing 12-month basis. An annual revenue growth of 49% is outstanding, Pre-tax margin of 15% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 10% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Rubicon Research Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-03 Quarterly Results
2025-11-13 Quarterly Results

Rubicon Research F&O

Rubicon Research Shareholding Pattern

59.99%
6.61%
0.39%
7.99%
0%
2.71%
22.31%

About Rubicon Research

  • NSE Symbol
  • RUBICON
  • BSE Symbol
  • 544578
  • Managing Director
  • Ms. Pratibha Pilgaonkar
  • ISIN
  • INE506V01022

Similar Stocks to Rubicon Research

Rubicon Research FAQs

Rubicon Research share price is ₹790 As on 05 February, 2026 | 16:49

The Market Cap of Rubicon Research is ₹13018.6 Cr As on 05 February, 2026 | 16:49

The P/E ratio of Rubicon Research is As on 05 February, 2026 | 16:49

The PB ratio of Rubicon Research is 20.1 As on 05 February, 2026 | 16:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23